American Capital Advisory’s Royalty Pharma RPRX Stock Holding History
Bought
Maintained
Sold
Other funds holding RPRX
American Capital Advisory's RPRX Position: Q3 2026 in Review
American Capital Advisory increased its Royalty Pharma (RPRX) stake by 1.1% in Q3 2026, buying an estimated $354 and bringing the position to 530 shares worth $30.9K. The position accounts for 0.01% of the portfolio, ranked #269.
American Capital Advisory first reported a position in RPRX in Q4 2023 and has held it in 12 quarters since. The position peaked at $36K in Q1 2024. 705 funds tracked by Wall St. Rank hold RPRX as of Q3 2026.
- American Capital Advisory held 530 shares of Royalty Pharma worth $30.9K as of Q3 2026.
- American Capital Advisory bought 6 Royalty Pharma shares in Q3 2026, an estimated $354.
- Royalty Pharma made up 0.01% of American Capital Advisory's portfolio in Q3 2026, its #269 holding.
- American Capital Advisory first reported a position in Royalty Pharma in Q4 2023 and has held it in 12 quarters since.
- American Capital Advisory's Royalty Pharma position peaked at $36K in Q1 2024.
- 705 funds tracked by Wall St. Rank held Royalty Pharma as of Q3 2026.
Based on American Capital Advisory's 13F filing for Q3 2026, filed 28 Oct 2026.